文献速递间质性肺疾病

基底膜修复生物标志物PRO-C4可预测特发性肺纤维化进展

Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts.
PubMed 文献 · Thorax · 2025-11-14

本研究基于PFBIO和PROFILE两个前瞻性多中心纵向队列,检测IPF患者血中IV型胶原合成标志物PRO-C4,发现进展者PRO-C4水平持续高于非进展者,高基线PRO-C4与死亡风险增加相关,提示PRO-C4是反映肺泡基底膜修复的预后生物标志物。

要点

  • 进展者PRO-C4纵向水平高于非进展者,PFBIO平均差异21.5%,PROFILE为10.9%。
  • PRO-C4月变化率在死亡者中更陡,且与肺功能变化呈负相关。
  • 高基线PRO-C4与PFBIO队列死亡风险增加相关(HR 2.55)。

核心结论

  • 高且升高的血清PRO-C4水平在两个独立IPF队列中可预后疾病进展。
  • PRO-C4评估的COL4合成是IPF肺泡基底膜修复的病理相关生物标志物。

研究设计与样本

  • 研究为前瞻性、多中心、观察性、纵向队列分析,纳入PFBIO和PROFILE两个队列的IPF患者。
  • PFBIO队列220例中51例(23.2%)在12个月时疾病进展;PROFILE队列459例中221例(48.1%)进展。
  • 采用线性混合效应回归模型比较12个月PRO-C4轨迹,贝叶斯双变量纵向模型比较PRO-C4与肺功能变化率,Cox比例风险模型分析基线PRO-C4与3年死亡率。
  • 通过免疫组化评估IPF与非IPF肺组织COL4染色。

主要发现

  • 进展者纵向PRO-C4水平高于非进展者:PFBIO平均差异21.5%(95%CI 3.4%至42.9%,p=0.0184);PROFILE平均差异10.9%(95%CI 0.8%至22.1%,p=0.0340)。
  • PRO-C4月变化率在死亡者中比存活者更陡(平均差异最高达3.12%,95%CI 0.35%至5.91%),且与肺功能变化呈负相关。
  • 高基线PRO-C4与PFBIO队列死亡风险增加相关(HR 2.55,95%CI 1.27至5.12,p=0.0083)。
  • COL4染色在IPF肺组织高于非IPF肺,但在终末期组织中不明显。

临床怎么用

  • 血清PRO-C4可作为IPF疾病进展和死亡风险的预后评估工具。
  • 动态监测PRO-C4水平变化可能有助于识别疾病进展风险较高的IPF患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterised by damage to the epithelial layer, closely associated with the alveolar basement membrane (BM). We aimed to investigate how type IV collagen (COL4) in the BM changes with the progression of IPF. METHODS: COL4 synthesis (PRO-C4) was detected in blood by the nordicPRO-C4 biomarker in patients with IPF from the two prospective, multicentre, observational, longitudinal cohorts, pulmonary fibrosis biomarker (PFBIO) and prospective observation of fibrosis in the lung clinical endpoints (PROFILE). PRO-C4 trajectories over 12 months were compared between progressors and non-progressors by linear mixed effects regression models. Rate of change in PRO-C4 and lung function were compared by Bayesian bivariate longitudinal models. Cox proportional hazards models analysed baseline PRO-C4 and 3 years mortality. COL4 staining in IPF and non-IPF lungs was evaluated by immunohistochemistry. RESULTS: In PFBIO and PROFILE, 51/220 (23.2%) and 221/459 (48.1%) patients, respectively, had progressive disease at 12 months. Longitudinal PRO-C4 levels were higher in progressors versus non-progressors (average differences: PFBIO 21.5% (95% CI 3.4% to 42.9%, p=0.0184); PROFILE 10.9% (95% CI 0.8% to 22.1%; p=0.0340). Monthly rate of change in PRO-C4 was steeper in non-survivors versus survivors (mean difference up to 3.12% (95% CI 0.35% to 5.91%)) and was inversely correlated with the change in lung function. High baseline PRO-C4 was associated with increased mortality risk in PFBIO (HR 2.55 (95% CI 1.27 to 5.12), p=0.0083). COL4 staining was higher in IPF versus non-IPF lung but was less obvious in end-stage tissue. CONCLUSIONS: High and increasing serological PRO-C4 levels were prognostic for progression in two independent IPF cohorts. This study suggests that COL4 synthesis assessed by PRO-C4 is a pathologically relevant biomarker of alveolar BM repair in IPF.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Sand JMB, Frederiksen P, John AE, et al. Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts. Thorax. 2025. PMID: 40537217. doi:10.1136/thorax-2024-221868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。